PMID- 27102154
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 21
DP  - 2016 May 24
TI  - The impact of adjuvant chemotherapy in older breast cancer patients on clinical 
      and biological aging parameters.
PG  - 29977-88
LID - 10.18632/oncotarget.8796 [doi]
AB  - PURPOSE: This prospective observational study aimed to evaluate the impact of 
      adjuvant chemotherapy on biological and clinical markers of aging and frailty. 
      METHODS: Women >/= 70 years old with early breast cancer were enrolled after 
      surgery and assigned to a chemotherapy (Docetaxel and Cyclophosphamide) group 
      (CTG, n=57) or control group (CG, n=52) depending on their planned adjuvant 
      treatment. Full geriatric assessment (GA) and Quality of Life (QoL) were 
      evaluated at inclusion (T0), after 3 months (T1) and at 1 year (T2). Blood 
      samples were collected to measure leukocyte telomere length (LTL), levels of 
      interleukin-6 (IL-6) and other circulating markers potentially informative for 
      aging and frailty: Interleukin-10 (IL-10), Tumor Necrosis Factor Alpha (TNF-alpha), 
      Insulin-like Growth Factor 1 (IGF-1), Monocyte Chemotactic Protein 1 (MCP-1) and 
      Regulated on Activation, Normal T cell Expressed and Secreted (RANTES). RESULTS: 
      LTL decreased significantly but comparably in both groups, whereas IL-6 was 
      unchanged at T2. However, IL-10, TNF-alpha, IGF-1 and MCP-1 suggested a minor 
      biological aging effect of chemotherapy. Clinical frailty and QoL decreased at T1 
      in the CTG, but recovered at T2, while remaining stable in the CG. CONCLUSIONS: 
      Chemotherapy (TC) is unlikely to amplify clinical aging or induce frailty at 1 
      year. Accordingly, there is no impact on the most established aging biomarkers 
      (LTL, IL-6).
FAU - Brouwers, Barbara
AU  - Brouwers B
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Hatse, Sigrid
AU  - Hatse S
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Dal Lago, Lissandra
AU  - Dal Lago L
AD  - Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, 
      Brussels, Belgium.
FAU - Neven, Patrick
AU  - Neven P
AD  - Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
FAU - Vuylsteke, Peter
AU  - Vuylsteke P
AD  - Department of Medical Oncology, Clinique et Maternite Sainte-Elisabeth, Namur, 
      Belgium.
FAU - Dalmasso, Bruna
AU  - Dalmasso B
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
AD  - Department of Internal Medicine, Istituto di Ricerca a Carattere Clinico e 
      Scientifico (IRCCS), Azienda Ospedaliera Universitaria (AOU) San Martino Istituto 
      Nazionale Tumori (IST), Genoa, Italy.
FAU - Debrock, Guy
AU  - Debrock G
AD  - Department of Medical Oncology, Ziekenhuizen Oost Limburg (ZOL), Genk, Belgium.
FAU - Van Den Bulck, Heidi
AU  - Van Den Bulck H
AD  - Department of Medical Oncology, Imelda Ziekenhuis Bondheiden, Belgium.
FAU - Smeets, Ann
AU  - Smeets A
AD  - Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
FAU - Bechter, Oliver
AU  - Bechter O
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Bailur, Jithendra Kini
AU  - Bailur JK
AD  - Department of Internal Medicine II, Centre for Medical Research, University of 
      Tubingen, Tubingen, Germany.
FAU - Kenis, Cindy
AU  - Kenis C
AD  - Department of General Medical Oncology and Geriatric Medicine, University 
      Hospitals Leuven, Belgium.
FAU - Laenen, Annouschka
AU  - Laenen A
AD  - Interuniversity Centre for Biostatistics and Statistical Bioinformatics, Leuven, 
      Belgium.
FAU - Schoffski, Patrick
AU  - Schoffski P
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
FAU - Pawelec, Graham
AU  - Pawelec G
AD  - Department of Internal Medicine II, Centre for Medical Research, University of 
      Tubingen, Tubingen, Germany.
AD  - School of Science and Technology, Nottingham Trent University, Nottingham, UK.
FAU - Journe, Fabrice
AU  - Journe F
AD  - Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, 
      Universite Libre de Bruxelles, Brussels, Belgium.
FAU - Ghanem, Ghanem-Elias
AU  - Ghanem GE
AD  - Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, 
      Universite Libre de Bruxelles, Brussels, Belgium.
FAU - Wildiers, Hans
AU  - Wildiers H
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, and 
      Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, Leuven, Belgium.
AD  - Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL5 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (IGF1 protein, human)
RN  - 0 (IL10 protein, human)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*drug effects
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Biomarkers/blood
MH  - Breast Neoplasms/*drug therapy/surgery
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL5/blood
MH  - Chemotherapy, Adjuvant/*adverse effects
MH  - Female
MH  - Frail Elderly
MH  - Frailty/etiology
MH  - Humans
MH  - Insulin-Like Growth Factor I/analysis
MH  - Interleukin-10/blood
MH  - Interleukin-6/blood
MH  - Leukocytes/drug effects
MH  - Prospective Studies
MH  - Quality of Life
MH  - Telomere/drug effects
MH  - Tumor Necrosis Factor-alpha/blood
PMC - PMC5058657
OTO - NOTNLM
OT  - Gerotarget
OT  - adjuvant chemotherapy
OT  - aging biomarkers
OT  - biological aging
OT  - breast cancer
OT  - older patients
COIS- The author(s) indicated no potential conflicts of interest.
EDAT- 2016/04/23 06:00
MHDA- 2017/12/30 06:00
PMCR- 2016/05/24
CRDT- 2016/04/23 06:00
PHST- 2016/02/16 00:00 [received]
PHST- 2016/04/08 00:00 [accepted]
PHST- 2016/04/23 06:00 [entrez]
PHST- 2016/04/23 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2016/05/24 00:00 [pmc-release]
AID - 8796 [pii]
AID - 10.18632/oncotarget.8796 [doi]
PST - ppublish
SO  - Oncotarget. 2016 May 24;7(21):29977-88. doi: 10.18632/oncotarget.8796.